ASCO GU 2025

Milestones of ADT and ARPI treatment in the metastastic…

What's the role of Enzalutamide in radioligand therapy?

MDT in OMPC

Darolutamide + ADT and Doetaxel improves survivas in…

Improved Survival with Enzalutamide + Lutetium

Final OS data for TALA + Enza

Mevrometostat - a new EZH2 inhibitor in mCRPC

Testosterone Recovery

Final OS analyses

Fish-oil supplement for pts on active surveillance

Mevrometostat + Enza: New option for mCRPC

OS in the TALAPRO-2 trial

Radical Prostatectomy VS RT in HRPC

Who benefits most from ARPIs?

Local radiotherapy of oligoprogressive mCRPC

ENZA-p showed OS benefit and improvement in QoL…

Phase 2 Mevrometostat

Darolutamide + ADT reduces risk of progression or death…

Radiation vs surgery in high risk prostate cancer

Testosterone Recovery after ADT and OS

Hypo-gonadism bad for survival?

Durvalumab in UTUC

Testosteron Geri Gelisi ve Sagkalim

Yuksek risk PCa da RP vs RT

Hangi hastalarda ADT+ARPI

Enza+Lu ile artmis sagkalim

UTUC de Neoadj. Durvalumab+Kemo

Exciting new substances - but don't over-estimate phase…

Triplet combination in RCC - there's no free lunch with…

KIM-1 - The most interesting biomarker for RCC?

Firstline Update Kidney Cancer

New data nccRCC

KIM-1 in CheckMate 214

KIM-1 in mRCC

New agents / new mode of actions

Casdatifan in refracting RCC

Proactive coaching of patients with TKI +/- IO therapy

Advanced Renal Cell Cancer: Adding more drugs does not…

Prognostic and predictive biomarkers in mRCC: Looking…

Biomarcadores prognósticos y predictivos en el CCRm: en…

Reassuring data on established ADCs and new insights in…

ADC + ICI - The future for MIBC?

Exploratory analyses of pCR in NIAGARA: who benefits…

New data, but no new insights for adjuvant treatment of…

New FGFR3 inhibitor

ASCO GU 25 - Summary: Urothelial Cancer

New drugs in mUC: The active field of ADCs

Updates neo/adjuvant therapy in MIBC

Neoadjuvant treatment for UTUC

Phase 2 Mevrometastat

Bladder-sparing approaches - are we there yet?

Preliminary results of neoadjuvant chemoimmunotherapy…

Promising combination for perioperative setting

HER2 - new marker for bladder preservation

EV-Pembro continues to be the standard for mTCC

The role of ctDNA in bladder cancer

Sacituzumab Tirumotecan shows promising antitumor…

Durvalumab + Platinum-based chemotherapy shows…

Adjuvant Nivo - independent from previous therapy

A possible new standard for mUC

Nuevos fármacos en mUC: El campo activo de las ADCs

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

RPLND in metastatic Seminoma

Metastatik seminomda Primer RPLND